Table 1 Characteristics of patients and unaffected fellow eyes at the first visit.

From: Association between subretinal fluid duration in central serous chorioretinopathy and chorioretinal structure in unaffected fellow eyes

Variables

Nonprolonged group

Prolonged group

Control group

Number of eyes

35

11

25

Age (years)

46.4 ± 8.9

45.8 ± 7.8

53.24 ± 13.7

Male/Female

28/7*

9/2

12/13*

Time from onset to initial visit (days)

10.5 ± 8.5

17.0 ± 10.4

–

Oral kallidinogenase use

17

6

–

Spherical equivalent (diopter)

– 1.35 ± 1.66

– 1.10 ± 1.97

– 1.30 ± 1.70

BCVA (LogMAR)

– 0.12 ± 0.07

– 0.14 ± 0.05

– 0.12 ± 0.08

CRT (µm)

189.2 ± 20.5

184.1 ± 9.73

183.4 ± 19.9

ONL (µm)

101.0 ± 14.4

93.8 ± 10.3

95.4 ± 17.1

CCT (µm)

294.4 ± 106.8*

362.5 ± 90.8**

213.5 ± 69.6*,**

LA (µm2)

281,670 ± 89,860

316,063 ± 61,753

244,306 ± 79,528

SA (µm2)

145,783 ± 58,248*

183,101 ± 42,042**

99,049 ± 18,340*,**

TCA (µm2)

427,454 ± 146,485*

499,164 ± 101,235**

337,674 ± 104,960*,**

CVI (%)

66.6 ± 3.3*

63.5 ± 2.3**

72.3 ± 5.1*,**

SRF duration (days)

54.1 ± 26.0*

143.3 ± 14.0*, †

–

  1. *, ** Significant difference between two groups (p < 0.05).
  2. † SRF duration of the affected eyes in the prolonged group was recorded only in six cases without topical treatments including intravitreous injection of anti-vascular endothelial growth factor agents, photodynamic therapy, or photocoagulation, because the other 5 cases received the treatment 3 months after the initial visit.
  3. BCVA best-corrected visual acuity, CCT central choroidal thickness, CRT central retinal thickness, CVI choroidal vascular index, LA luminal area, LogMAR Converted to the logarithm of the minimal angle of resolution, ONL outer nuclear layer thickness, SA stromal area, SRF subretinal fluid, SRF duration, time from initial visit to SRF resolution, TCA total choroidal area.
Back to article page